Spotlight on eltrombopag concentration in pediatric immune thrombocytopenia: A single-center observational study in China.

Eltrombopag proves efficacious and well-tolerated for treating pediatric ITP. However, prolonged and high-dose administration may increase the likelihood of ADRs. Thus, examining the appropriate eltrombopag concentration assists in directing individualized management of pediatric ITP.